{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:30:46Z","timestamp":1790199046589,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.ahj.2005.09.025","type":"journal-article","created":{"date-parts":[[2005,12,13]],"date-time":"2005-12-13T07:27:06Z","timestamp":1134458826000},"page":"1107.e1-1107.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)\u20135 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non\u2013ST-segment elevation acute coronary syndromes"],"prefix":"10.1016","volume":"150","member":"78","reference":[{"key":"10.1016\/j.ahj.2005.09.025_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199201233260406","article-title":"The pathogenesis of coronary artery disease and acute coronary syndromes","volume":"326","author":"Fuster","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.09.025_bib2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(97)11162-X","article-title":"Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without ST elevation","volume":"352","author":"Yusuf","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2005.09.025_bib3","doi-asserted-by":"crossref","first-page":"95S","DOI":"10.1378\/chest.119.1_suppl.95S","article-title":"New anticoagulant drugs","volume":"119","author":"Weitz","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2005.09.025_bib4","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/ajhp\/58.suppl_2.S14","article-title":"Fondaparinux sodium: a selective inhibitor of factor Xa","volume":"58","author":"Bauer","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ahj.2005.09.025_bib5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM200103013440901","article-title":"A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement","volume":"344","author":"Turpie","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.09.025_bib6","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2005.09.025_bib7","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2005.09.025_bib8","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.09.025_bib9","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.09.025_bib10","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"Buller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.09.025_bib11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2005.09.025_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-0037-1614445","article-title":"Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent\u2014a pilot study in the setting of coronary angioplasty","volume":"81","author":"Vuillemenot","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2005.09.025_bib13","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/euhj.2001.2777","article-title":"A synthetic factor-Xa inhibitor (ORG31540\/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study","volume":"22","author":"Coussement","year":"2001","journal-title":"Eur J Heart"},{"key":"10.1016\/j.ahj.2005.09.025_bib14","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.jacc.2004.02.051","article-title":"A dose-finding study of fondaparinux in patients with non ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) study","volume":"43","author":"Simoons","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2005.09.025_bib15","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/01.CIR.0000158485.70761.67","article-title":"Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial","volume":"111","author":"Mehta","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2005.09.025_bib16","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis","volume":"355","author":"Eilkelboom","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2005.09.025_bib17","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1001\/jama.293.23.2908","article-title":"Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials","volume":"293","author":"Mehta","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2005.09.025_bib18","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","volume":"344","author":"Cannon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2005.09.025_bib19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0140-6736(99)07349-3","article-title":"FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators: invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2005.09.025_bib20","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.290.12.1593","article-title":"Evaluation of prolonged antithrombotic pretreatment (\u201ccooling-off\u201d strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial","volume":"290","author":"Neumann","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2005.09.025_bib21","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1046\/j.1538-7836.2003.00536.x","article-title":"Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux","volume":"1","author":"Lisman","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2005.09.025_bib22","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870305009385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870305009385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:15:43Z","timestamp":1757567743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870305009385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0002870305009385"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2005.09.025","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)\u20135 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non\u2013ST-segment elevation acute coronary syndromes","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2005.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}